304 related articles for article (PubMed ID: 23164683)
1. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
Kanellopoulou T; Alexopoulou A
Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
[TBL] [Abstract][Full Text] [Related]
3. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
5. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.
Lazaraki G; Akriviadis E; Pilpilidis I; Parisi I; Tzilves D; Tarpangos A
Am J Gastroenterol; 2011 Dec; 106(12):2204-6. PubMed ID: 22138950
[No Abstract] [Full Text] [Related]
6. Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia.
Kline RM; Buck LM
Pediatr Blood Cancer; 2009 Apr; 52(4):534-6. PubMed ID: 19101995
[TBL] [Abstract][Full Text] [Related]
7. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
8. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
[TBL] [Abstract][Full Text] [Related]
10. Hereditary hemorrhagic telangiectasia/avastin.
Davidson TM; Olitsky SE; Wei JL
Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
Villanueva B; Iriarte A; Torres-Iglesias R; Muñoz Bolaño M; Cerdà P; Riera-Mestre A
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763652
[TBL] [Abstract][Full Text] [Related]
12. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
Alderman C; Corlett J; Cullis J
Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440
[No Abstract] [Full Text] [Related]
13. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Epperla N; Hocking W
Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
[TBL] [Abstract][Full Text] [Related]
14. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
Karnezis TT; Davidson TM
Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Karnezis TT; Davidson TM
Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
[TBL] [Abstract][Full Text] [Related]
18. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
19. [Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report].
Mozdon MA; Ponomarev RV; Tsvetaeva NV; Shabrin AV; Ermachenkova EI; Larichev SE; Lukina EA
Ter Arkh; 2023 Sep; 95(7):580-585. PubMed ID: 38159009
[TBL] [Abstract][Full Text] [Related]
20. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.
Flieger D; Hainke S; Fischbach W
Ann Hematol; 2006 Sep; 85(9):631-2. PubMed ID: 16807748
[No Abstract] [Full Text] [Related]
[Next] [New Search]
